Add Formweb to your mobile device
Search results for:
Olanzapine
OLANZapine
| Drug Name | Form | Strength | Notes |
|---|---|---|---|
| Olanzapine | POWDER FOR INJECTION, INTRAMUSCULAR | 10 mg | |
| Olanzapine | TABLET, DISINTEGRATING, ORAL | 5 mg | |
| Olanzapine | TABLET, DISINTEGRATING, ORAL | 10 mg | |
| Olanzapine | TABLET, ORAL | 2.5 mg | |
| Olanzapine | TABLET, ORAL | 5 mg | |
| Olanzapine | TABLET, ORAL | 7.5 mg | |
| Olanzapine | TABLET, ORAL | 10 mg | |
| Olanzapine | TABLET, ORAL | 15 mg | |
| Olanzapine | TABLET, ORAL | 20 mg | |
| Zyprexa |
VIEW MORE Atypical Antipsychotics
Last updated: Apr. 28, 2026
- Black Box Warning: Mortality in elderly with dementia related psychosis
- REMS: Zyprexa Relprevv, kit-FDA REMS Info
- REMS: Legacy Health REMS Requirements-Olanzapine
control (often in your face, tongue or jaw)
Injectable olanzapine given intravenous (IV) is an off-label route. It is only labeled for intramuscular (IM) use.
Adverse reactions with olanzapine IM and IV may include: dizziness, drowsiness, postural hypotension, bradycardia, and respiratory depression.
Monitor the patient closely. If dizziness and/or drowsiness are noted, the patient should remain recumbent until examination indicates postural hypotension and/or bradycardia are not a problem
Olanzapine IM/IV 10 mg (Zyprexa): reconstitute with 2.1 mL sterile water. Final concentration = 5 mg/mL. Use immediately after reconstitution. See Package Insert.
Use for delirium in a ventilated Critical Care patient: See Guideline 901.5008
Olanzapine extended-release injectable suspension (Zyprexa Relprevv®) has not been requested for formulary status and is not routinely stocked by sites due to the REMS program. The goal of the Zyprexa Relprevv REMS is to mitigate the risk of negative outcomes associated with post-injection delirium/sedation syndrome (PDSS), and includes health care provider, patient, pharmacy and health care settings requirements for dispensing.
See Legacy Health REMS Requirements for detail.